Skip to main content
. 2020 Nov 30;58(231):893–899. doi: 10.31729/jnma.5216

Table 3. Antibiotic sensitivity pattern of major isolates.

Antibiotics A. baumannii S*/(S + R) (%) Enterobacter spp. S/(S + R) (%) K. pneumoniae S/(S + R) (%) P. aeruginosa S/(S + R) (%) E. coli S/(S + R) (%) K. oxytoca S/(S + R) (%) S. aureus S/(S + R) (%)
Ampicillin 1/27 (3.7) 0/14 (0) 0/16 (0) 0/12 (0) 1/3 (33.3) 0/2 (0) 3/5 (60)
Ampicillin/Sulbactum 10/19 (52.6) 1/13 (7.7) 0/15 (0) 1/8 (12.5) NT 0/2 (0) 3/5 (60)
Cefotaxime 6/27 (22.2) 2/14 (14.3) 2/16 (12.5) 7/12 (28.2) 3/3 (100) 0/2 (0) 1/5 (20)
Ceftriaxone 6/27 (22.2) 2/14 (14.3) 1/16 (6.3) 6/12 (50) 3/3 (100) 0/2 (0) 2/5 (40)
Cefoperazone/Sulbactum 14/17 (82.4) 0/8 (0) 0/11 (0) 8/8 (100) NT ½ (50) NT
Cefepime 7/15 (46.7) 1/7 (14.3) 2/7 (28.6) 1/5 (20) NT ½ (50) 2/2 (100)
Cotrimoxazole 16/27 (59.3) 2/14 (14.3) 7/15 (46.7) 3/12 (25) 3/3 (100) 0/2 (0) 1/1 (100)
Gentamicin 17/27 (63) 1/14 (7.1) 2/16 (12.5) 7/12 (58.3) 3/3 (100) 0/2 (0) 3/5 (60)
Amikacin 16/27 (59.3) 1/14 (7.1) 2/16 (12.5) 11/12 (91.7) 3/3 (100) 0/2 (0) 5/5 (100)
Ofloxacin 20/27 (74.1) 12/13 (92.3) 9/15 (60) 11/11 (100) 2/2 (100) 0/2 (0) 1/3 (33.3)
Levofloxacin 22/27 (81.5) 12/13 (92.3) 10/15 (66.7) 11/11 (100) 2/2 (100) ½ (50) 3/3 (100)
Imipinem 13/14 (92.9) 8/9 (88.9) 7/8 (87.5) 5/5 (100) NT 2/2 (100) 2/3 (66.7)
Meropenem 25/27 (92.6) 14/14 (100) 14/16 (87.5) 12/12 (100) 2/2 (100) 2/2 (100) 5/5 (100)
Colistin 15/15 (100) NT 10/10 (100) 5/5 (100) NT 2/2 (100) 1/2 (50)
Tigecycline 15/15 (100) 5/6 (83.3) 6/6 (100) 2/5 (40) NT 1/1 (100) 2/2 (100)
Polymixin 15/15 (100) 5/6 (83.3) 7/8 (87.5) 4/5 (80) NT 2/2 (100) ½ (50)
Piperacillin/Tazobactum NT NT NT 8/9 (88.9) NT NT NT
Norfloxacin NT NT 1/3 (33.3) NT 3/3 (100) NT NT
Chloram phenicol 2/2 (100) 3/3 (100) 2/3 (66.7) 0/2 (0) NT NT NT
Penicillin NT NT NT NT NT NT 0/5 (0)
Cloxacillin NT NT NT NT NT NT 2/5 (40)
Vancomycin NT NT NT NT NT NT 5/5 (100)
Azithromycin 1/12 (8.3) 2/13 (15.4) 0/14 (0) 0/7 (0) NT 0/2 (0) 2/5 (40)
*

S= Sensitive;

R = Resistant;

NT = Not Tested.